Clinical Trials Logo

Filter by:
NCT ID: NCT01429337 Completed - Hepatic Impairment Clinical Trials

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Start date: March 7, 2011
Phase: Phase 1
Study type: Interventional

The purpose of this international study was to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.

NCT ID: NCT01428453 Completed - Alzheimer's Disease Clinical Trials

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Start date: October 1, 2011
Phase: Phase 2
Study type: Interventional

The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.

NCT ID: NCT01427972 Completed - Clinical trials for Chronic Kidney Disease

A Study of LY2623091 in Male and Females With Chronic Kidney Disease

Start date: September 2011
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to investigate the safety and efficacy of LY2623091 in males and females with chronic kidney disease.

NCT ID: NCT01425359 Completed - Clinical trials for Coronary Artery Disease

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

TERISA
Start date: September 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.

NCT ID: NCT01424566 Completed - Pain Clinical Trials

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Start date: June 29, 2012
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to evaluate the efficacy of nabiximols (Sativex®), compared with placebo, when used as an adjunctive measure in relieving uncontrolled persistent chronic pain (not breakthrough pain) in participants with advanced cancer, who had inadequate analgesia even with optimized chronic opioid therapy. This multi-center study was conducted in two parts. All participants enrolled into the trial received nabiximols during one of two parts of the study, but they did not know which part. Eligible participants were not required to stop any of their current treatments or medications.

NCT ID: NCT01422876 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Start date: August 2011
Phase: Phase 3
Study type: Interventional

This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.

NCT ID: NCT01422720 Completed - Epilepsy Clinical Trials

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Start date: April 2010
Phase: Phase 4
Study type: Interventional

This is an open Label study to investigate the safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients.

NCT ID: NCT01419665 Completed - Follicular Lymphoma Clinical Trials

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

ASSIST_FL
Start date: December 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.

NCT ID: NCT01418352 Completed - Tourette's Disorder Clinical Trials

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Start date: August 2, 2011
Phase: Phase 3
Study type: Interventional

The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.

NCT ID: NCT01416441 Completed - Tourette's Disorder Clinical Trials

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start date: October 19, 2011
Phase: Phase 3
Study type: Interventional

The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.